Orexo AB (publ) (ORX.ST)
- Previous Close
17.00 - Open
17.00 - Bid 16.14 x --
- Ask 16.48 x --
- Day's Range
16.02 - 17.16 - 52 Week Range
8.44 - 20.10 - Volume
19,414 - Avg. Volume
18,045 - Market Cap (intraday)
585.643M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-3.73 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.00
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
www.orexo.com116
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ORX.ST
Performance Overview: ORX.ST
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORX.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORX.ST
Valuation Measures
Market Cap
569.80M
Enterprise Value
872.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.92
Price/Book (mrq)
9.94
Enterprise Value/Revenue
1.37
Enterprise Value/EBITDA
-39.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-20.08%
Return on Assets (ttm)
-2.95%
Return on Equity (ttm)
-101.50%
Revenue (ttm)
638.8M
Net Income Avi to Common (ttm)
-128.3M
Diluted EPS (ttm)
-3.73
Balance Sheet and Cash Flow
Total Cash (mrq)
171M
Total Debt/Equity (mrq)
804.41%
Levered Free Cash Flow (ttm)
-21.49M
Research Analysis: ORX.ST
Company Insights: ORX.ST
ORX.ST does not have Company Insights